Galmed Pharmaceuticals CEO Letter: Strong Cash Position and Strategic Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Should l Buy GLMD?
Galmed Pharmaceuticals issued a Letter to Shareholders from Allen Baharaff, Chief Executive Officer. "Over the past year, we have successfully expanded our therapeutic focus beyond liver disease, generating compelling new data that supports a broader clinical development path for Aramchol in oncology and cardiometabolic indications... My message to investors is clear: Galmed is well-capitalized, scientifically advancing on multiple fronts, and positioned for meaningful growth opportunities. 1. Strong Cash Position and Prudent Financial Stewardship. Galmed ended the third quarter of 2025 with approximately $19.2 million in cash and practically zero debt on our balance sheet... 2. Significant Clinical Advancements. Aramchol for MASH and liver fibrosis... Aramchol for Gastrointestinal oncology indications... Expansion Potential Beyond MASH and Oncology... Looking Ahead: In summary, I want to emphasize the following: Galmed remains financially strong, with sufficient resources to support our current strategic and clinical plans. Our scientific progress has been exceptional, with multiple breakthroughs validating and expanding the potential of Aramchol across high-value therapeutic areas. We are committed to short and long-term value creation, grounded in disciplined execution, scientific innovation, and responsible financial stewardship. Throughout this process, we aim to maintain transparency, careful capital allocation, and clear communication with our shareholders."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLMD
About GLMD
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galmed Pharmaceuticals Receives Nasdaq Compliance Notice
- Compliance Notice: Galmed Pharmaceuticals received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1 per share, necessitating compliance restoration within 180 days until July 28, 2026.
- Restoration Requirements: The company must maintain a closing bid price of at least $1 for a minimum of 10 consecutive business days; failure to do so may allow for an additional compliance period, contingent on meeting other listing requirements.
- Stock Price Impact: Following the notice, Galmed's stock price fell by 5.33% to $0.71, reflecting market sensitivity to compliance risks and potential implications for the company's future financing capabilities.
- Trading Impact: Despite the compliance notice, Galmed stated that it has no immediate effect on its trading on the Nasdaq Capital Market, indicating the company is actively managing its listing status.
See More
Galmed Pharmaceuticals Receives Nasdaq Compliance Notice
- Compliance Notice: Galmed Pharmaceuticals received a letter from Nasdaq indicating non-compliance with the minimum bid price of $1.00 per share, requiring compliance within 180 days to avoid potential delisting risks.
- Compliance Period: The company has until July 28, 2026, to regain compliance; if the closing bid price reaches $1 for ten consecutive business days during this period, it will receive written confirmation of compliance, thus avoiding delisting.
- Market Impact: Although the notice does not immediately affect the company's Nasdaq listing, failure to regain compliance could negatively impact investor confidence and stock price.
- Strategic Development: Galmed focuses on the development of Aramchol for liver diseases and other related conditions, actively pursuing diversification of its product pipeline to address market competition.
See More
Galmed Pharmaceuticals Faces Nasdaq Compliance Challenge
- Compliance Notification: Galmed Pharmaceuticals received a compliance letter from Nasdaq indicating that its ordinary shares failed to meet the minimum bid price requirement of $1.00 per share, which could jeopardize its continued listing status.
- Grace Period: The company has been granted a 180-day grace period, from January 29, 2026, to July 28, 2026, during which it can regain compliance if its share price meets the required threshold for ten consecutive trading days.
- Potential Consequences: Failure to regain compliance by the end of the grace period may result in Galmed facing delisting from Nasdaq, which could negatively impact its financing capabilities and market confidence.
- Business Development Strategy: Despite compliance challenges, Galmed continues to actively advance the development of Aramchol, focusing on treatments for liver diseases and cardiometabolic conditions, demonstrating its long-term commitment to innovative drug development.
See More
Galmed Pharmaceuticals to Initiate Phase 1/2 Trial of Aramchol and Regorafenib in 2026
- Clinical Trial Launch: Galmed Pharmaceuticals announced the initiation of a Phase 1/2 clinical trial for the combination of Aramchol and Regorafenib in 2026, aimed at enhancing treatment efficacy for hepatocellular carcinoma and other GI cancers, marking a significant advancement in the company's liver disease treatment efforts.
- Scientific Rationale Strengthened: Research indicates that Aramchol significantly enhances Bayer's Regorafenib efficacy in GI cancer models through SCD1 inhibition, providing a solid scientific foundation for the upcoming clinical trial.
- Investor Value Enhancement: Positive outcomes from the clinical trial could lay the groundwork for expanding Galmed's oncology pipeline, potentially attracting more investor interest and increasing the company's overall market value.
- Industry Recognition: The acceptance of Galmed's latest research findings at the HEP-DART 2025 meeting underscores the significance of its work in liver disease treatment, further enhancing the company's competitive position in the market.
See More
Galimedix Reports Excellent Phase 1 Results for GAL-101 with No Adverse Events
- Clinical Trial Success: Galimedix presented Phase 1 study results for GAL-101 at CTAD 2025, involving approximately 100 healthy volunteers, demonstrating excellent safety and tolerability with no dose-limiting adverse events, indicating the drug's potential in Alzheimer's treatment.
- Drug Penetration Capability: GAL-101 confirmed effective blood-brain barrier penetration with lumbar CSF concentrations after multiple doses, supporting a once-daily dosing regimen for future trials, which may enhance patient adherence to treatment.
- Future Research Planning: Following positive Phase 1 results, Galimedix is planning a Phase 2 proof-of-concept study in Alzheimer's disease, expected to include cognitive functional endpoints and biomarkers to capture early signs of cognitive improvement.
- Technological Innovation: As a small molecule targeting misfolded amyloid beta monomers to prevent toxic aggregate formation, GAL-101 shows broad application prospects in treating Alzheimer's disease, dry age-related macular degeneration, and glaucoma.
See More
Galmed Secures New Patent for Aramchol, Extending Protection to 2042
- Patent Protection Extension: Galmed Pharmaceuticals has secured a new use patent for Aramchol in South Korea, extending global patent protection to 2042, thereby reinforcing its market leadership in the non-alcoholic steatohepatitis (NASH) sector.
- Clinical Readiness: As a first-in-class candidate ready for Phase 3 trials, Aramchol has demonstrated significant fibrosis improvement in clinical studies, indicating its potential in treating complex diseases.
- Combination Therapy Outlook: The new patent covers the combination therapy of Aramchol and Rezdiffra, aligning with the industry's shift towards combination therapies, which is expected to drive the initiation of clinical studies and meet market demand for effective treatments.
- Safety Advantage: Aramchol's excellent safety and tolerability make it an ideal candidate for combination with other MASH drugs, potentially enhancing its market acceptance and driving sales growth.
See More
Galmed Pharmaceuticals Receives Nasdaq Compliance Notice
- Compliance Notice: Galmed Pharmaceuticals received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1 per share, necessitating compliance restoration within 180 days until July 28, 2026.
- Restoration Requirements: The company must maintain a closing bid price of at least $1 for a minimum of 10 consecutive business days; failure to do so may allow for an additional compliance period, contingent on meeting other listing requirements.
- Stock Price Impact: Following the notice, Galmed's stock price fell by 5.33% to $0.71, reflecting market sensitivity to compliance risks and potential implications for the company's future financing capabilities.
- Trading Impact: Despite the compliance notice, Galmed stated that it has no immediate effect on its trading on the Nasdaq Capital Market, indicating the company is actively managing its listing status.
See More
Galmed Pharmaceuticals Receives Nasdaq Compliance Notice
- Compliance Notice: Galmed Pharmaceuticals received a letter from Nasdaq indicating non-compliance with the minimum bid price of $1.00 per share, requiring compliance within 180 days to avoid potential delisting risks.
- Compliance Period: The company has until July 28, 2026, to regain compliance; if the closing bid price reaches $1 for ten consecutive business days during this period, it will receive written confirmation of compliance, thus avoiding delisting.
- Market Impact: Although the notice does not immediately affect the company's Nasdaq listing, failure to regain compliance could negatively impact investor confidence and stock price.
- Strategic Development: Galmed focuses on the development of Aramchol for liver diseases and other related conditions, actively pursuing diversification of its product pipeline to address market competition.
See More
Galmed Pharmaceuticals Faces Nasdaq Compliance Challenge
- Compliance Notification: Galmed Pharmaceuticals received a compliance letter from Nasdaq indicating that its ordinary shares failed to meet the minimum bid price requirement of $1.00 per share, which could jeopardize its continued listing status.
- Grace Period: The company has been granted a 180-day grace period, from January 29, 2026, to July 28, 2026, during which it can regain compliance if its share price meets the required threshold for ten consecutive trading days.
- Potential Consequences: Failure to regain compliance by the end of the grace period may result in Galmed facing delisting from Nasdaq, which could negatively impact its financing capabilities and market confidence.
- Business Development Strategy: Despite compliance challenges, Galmed continues to actively advance the development of Aramchol, focusing on treatments for liver diseases and cardiometabolic conditions, demonstrating its long-term commitment to innovative drug development.
See More
Galmed Pharmaceuticals to Initiate Phase 1/2 Trial of Aramchol and Regorafenib in 2026
- Clinical Trial Launch: Galmed Pharmaceuticals announced the initiation of a Phase 1/2 clinical trial for the combination of Aramchol and Regorafenib in 2026, aimed at enhancing treatment efficacy for hepatocellular carcinoma and other GI cancers, marking a significant advancement in the company's liver disease treatment efforts.
- Scientific Rationale Strengthened: Research indicates that Aramchol significantly enhances Bayer's Regorafenib efficacy in GI cancer models through SCD1 inhibition, providing a solid scientific foundation for the upcoming clinical trial.
- Investor Value Enhancement: Positive outcomes from the clinical trial could lay the groundwork for expanding Galmed's oncology pipeline, potentially attracting more investor interest and increasing the company's overall market value.
- Industry Recognition: The acceptance of Galmed's latest research findings at the HEP-DART 2025 meeting underscores the significance of its work in liver disease treatment, further enhancing the company's competitive position in the market.
See More
Galimedix Reports Excellent Phase 1 Results for GAL-101 with No Adverse Events
- Clinical Trial Success: Galimedix presented Phase 1 study results for GAL-101 at CTAD 2025, involving approximately 100 healthy volunteers, demonstrating excellent safety and tolerability with no dose-limiting adverse events, indicating the drug's potential in Alzheimer's treatment.
- Drug Penetration Capability: GAL-101 confirmed effective blood-brain barrier penetration with lumbar CSF concentrations after multiple doses, supporting a once-daily dosing regimen for future trials, which may enhance patient adherence to treatment.
- Future Research Planning: Following positive Phase 1 results, Galimedix is planning a Phase 2 proof-of-concept study in Alzheimer's disease, expected to include cognitive functional endpoints and biomarkers to capture early signs of cognitive improvement.
- Technological Innovation: As a small molecule targeting misfolded amyloid beta monomers to prevent toxic aggregate formation, GAL-101 shows broad application prospects in treating Alzheimer's disease, dry age-related macular degeneration, and glaucoma.
See More
Galmed Secures New Patent for Aramchol, Extending Protection to 2042
- Patent Protection Extension: Galmed Pharmaceuticals has secured a new use patent for Aramchol in South Korea, extending global patent protection to 2042, thereby reinforcing its market leadership in the non-alcoholic steatohepatitis (NASH) sector.
- Clinical Readiness: As a first-in-class candidate ready for Phase 3 trials, Aramchol has demonstrated significant fibrosis improvement in clinical studies, indicating its potential in treating complex diseases.
- Combination Therapy Outlook: The new patent covers the combination therapy of Aramchol and Rezdiffra, aligning with the industry's shift towards combination therapies, which is expected to drive the initiation of clinical studies and meet market demand for effective treatments.
- Safety Advantage: Aramchol's excellent safety and tolerability make it an ideal candidate for combination with other MASH drugs, potentially enhancing its market acceptance and driving sales growth.
See More
